GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-03-10|

BioNTech and Regeneron Expands Cancer Vaccine Collab, Adds Lung Cancer Indication

by Joy Lin
Share To

BioNTech and Regeneron have been combining the former’s mRNA-based FixVac platform with the latter’s PD-1 immune checkpoint inhibitor, Libtayo, to generate cancer vaccines. Now, the two companies are adding a third tumor type – advanced non-small cell lung cancer (NSCLC) – to their collaboration. 

NSCLC is one of the most common forms of lung cancer, making up about 85% of all lung cancers.

Under the deal, the companies will start evaluating BioNTech’s candidate BNT116 with Libtayo as a first-line treatment for patients with advanced NSCLC. The companies will equally share development costs for the trials. Separately, BioNTech wll conduct a Phase 1 called LuCa-MERIT-1 assessing the BNT116/Libtayo combo in other NSCLC subpopulations. Full financial details of the deal have not been disclosed, similar to previous agreements. 

“We are delighted to expand our collaboration with BioNTech to a third tumor type – advanced NSCLC – and investigate whether combining Libtayo with BNT116 will further enhance the efficacy and safety we’ve demonstrated with Libtayo in this cancer as both a monotherapy and in combination with chemotherapy,” said Israel Lowy, Senior Vice President of Clinical Development, Oncology, at Regeneron. “Combining PD-1 inhibition with mRNA-based vaccines is an exciting, yet still emerging, approach in oncology.”

 

Related article: New Research on Neoantigens and Tumor-targeting T-cells Marks Paradigm Shift in Countering Solid Tumors

 

FixVac and Cancer Vaccine Candidates

 

BioNTech’s FixVac selects combinations of mRNA encoding for known cancer-specific antigens expressed by many cancerous cells. In the case of BNT116, the mRNA vaccine candidate encodes for a cluster of antigens frequently seen on NSCLC cells. 

Besides NSCLC, BioNTech has ongoing partnerships with Regeneron to develop cancer vaccines against advanced melanoma and prostate cancer. The experimental shots also use a combination of FixVac candidates and Libtayo.

Outside the partnership, BioNTech’s FixVac pipeline includes a Phase 2 asset for HPV-positive head and neck cancers and a Phase 1 drug for ovarian cancer. 

“Advancing the sixth FixVac product candidate based on uridine mRNA into clinical development underlines the versatility and potential of this platform,” said Özlem Türeci, Co-Founder and Chief Medical Officer at BioNTech.

The five-year survival rate of advanced NSCLC is only 25% leaving patients, and there are few treatment options. 

“We believe that a potent vaccine that induces strong T cell responses against shared tumor associated antigens combined with PD-1 blockade that further enables the activated T cell repertoire will help to address the high unmet medical need in this indication,” said Türeci.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
JPM 2025 Looks at the Cell and Gene Therapy Landscape – Autoimmune, Cancer, and Chronic Diseases are Front and Center
2025-01-21
Cecile Richards’s Battle with Glioblastoma
2025-01-21
Neuro, Pain, and Cancer Top the List at JPM 2025 Healthcare Conference
2025-01-17
LATEST
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation
2025-02-11
Trump’s Trade War Shake-Up: How U.S. Tariffs Could Disrupt Global Pharma
2025-02-10
Precision Medicine Market Skyrocketing, Shaking the Industry with $470.53 Billion Expected by 2034
2025-02-10
Super Bowl LIX and the Biotech Sector: A New Arena for Engagement
2025-02-09
What the PlayStation Network Outage Can Teach the Biotech Industry
2025-02-08
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
Scroll to Top